Stanniocalcin expression as a predictor of late breast cancer recurrence

**Supplementary data**

Supplementary Table S1 contains information on the association between STC1 and STC2 expression and breast cancer recurrence by median time to recurrence in years, for five quintiles of time, among estrogen-receptor (ER) negative breast cancer patients not treated with tamoxifen (TAM-).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table S1. Association between STC1 and STC2 expression and BC recurrence, by median time to recurrence, ER-/TAM- patient group.** | | | | | | | |
|  | STC1a | | |  | STC2a | | |
| Median time to recurrence (yrs) b | Recurrent cases/ controls | OR (95% CI)c | aOR (95% CI)d |  | Recurrent cases/ controls | OR (95% CI)c | aOR (95% CI)d |
| 1.5 | 111/109 | 0.83 (0.46, 1.52) | 0.78 (0.41, 1.46) |  | 109/101 | 0.97 (0.53, 1.75) | 0.95 (0.50, 1.80) |
| 2.3 | 66/70 | 1.17 (0.51, 2.65) | 0.92 (0.35, 2.46) |  | 64/68 | 1.20 (0.57, 2.51) | 2.15 (0.82, 5.61) |
| 3.3 | 32/33 | 1.13 (0.33, 3.81) | 1.35 (0.34, 5.43) |  | 31/31 | 0.82 (0.26, 2.61) | 0.58 (0.12, 2.82) |
| 4.6 | 25/24 | 1.88 (0.42, 8.32) | § |  | 24/22 | 0.70 (0.16, 3.15) | § |
| 7.9 | 18/17 | 0.49 (0.07, 3.36) | § |  | 17/15 | 0.50 (0.07, 3.58) | § |
| a Expression of STC1 and STC2 dichotomized as positive (>0%) or negative (0%).  b Median time to recurrence based on recurrent cases.  c Based on unconditional logistic regression model, adjusting for matched factors: age group, year group of diagnosis, menopausal status,  Stage (I-III), and county of treatment.  d Adjusted OR includes matched factors and chemotherapy, radiation, CCI group, and tamoxifen duration (ER+).  § Estimate uninterpretable. | | | | | | | |